Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-... by Aletaha, Daniel, MD, Bingham, Clifton O, MD, Tanaka, Yoshiya, Prof, Agarwal, Prasheen, PhD, Kurrasch, Regina, MD, Tak, Paul P, Prof, Popik, Sharon, MD

Get full text

Epidemiology and Treatment of New‐Onset and Established Rheumatoid Arthritis in an Insured US Population by Crane, Martin M., Juneja, Maneesh, Allen, Jeffery, Kurrasch, Regina H., Chu, Myron E., Quattrocchi, Emilia, Manson, Stephanie C., Chang, David J.

Get full text

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis by Schmidt, Wolfgang A., Dasgupta, Bhaskar, Luqmani, Raashid, Unizony, Sebastian H., Blockmans, Daniel, Lai, Zhihong, Kurrasch, Regina H., Lazic, Ivana, Brown, Kurt, Rao, Ravi

Get full text

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study by Bae, Sang-Cheol, Bass, Damon L, Chu, Myron, Curtis, Paula, Dimelow, Richard, Harvey, Laurence, Ji, Beulah, Kurrasch, Regina, Muzaffar, Saima, Punwaney, Raj, Roth, David A, Song, Yeong-Wook, Xie, Wendy, Zhang, Fengchun

Get full text

Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study by Tanaka, Yoshiya, Curtis, Paula, DeRose, Kathleen, Kurrasch, Regina, Kinoshita, Kyoko, Tanaka, Rika, Yamazaki, Yumi, Roth, David A

Get full text

Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses by Zheng, Jie, Gu, Jieruo, Su, Yin, Li, Yang, Li, Xingfu, Xiong, Cui, Cao, Hua, Quasny, Holly, Chu, Myron, Curtis, Paula, DeRose, Kathleen, Kurrasch, Regina, Meizlik, Paige, Roth, David A, Zhang, Fengchun

Get full text

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials by Quattrocchi, Emilia, Østergaard, Mikkel, Taylor, Peter C, van Vollenhoven, Ronald F, Chu, Myron, Mallett, Stephen, Perry, Hayley, Kurrasch, Regina

Get full text

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea by Tanaka, Yoshiya, Bae, Sang-Cheol, Bass, Damon, Curtis, Paula, Chu, Myron, DeRose, Kathleen, Ji, Beulah, Kurrasch, Regina, Lowe, Jenny, Meizlik, Paige, Roth, David A

Get full text

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years by Zhang, Fengchun, Zheng, Jie, Li, Yang, Wang, Guochun, Wang, Mingjun, Su, Yin, Gu, Jieruo, Li, Xingfu, Bass, Damon, Chu, Myron, Curtis, Paula, DeRose, Kathleen, Kurrasch, Regina, Lowe, Jenny, Meizlik, Paige, Roth, David A

Get full text

Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study by Thorne, Carter, Takeuchi, Tsutomu, Karpouzas, George Athanasios, Sheng, Shihong, Kurrasch, Regina, Fei, Kaiyin, Hsu, Benjamin

Get full text

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics by KURRASCH, Regina, BROWN, Judith C, CHU, Myron, CRAIGEN, Jenny, OVEREND, Philip, PATEL, Bela, WOLFE, Steven, CHANG, David J

Get full text